What question did this study set out to answer?

This research aims to classify acute myeloid leukemia (AML) subtypes and find associated therapeutic targets through a multiomics approach.

June 14, 2026Nature CancerOpen Access

Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial identifies molecular subtypes and therapy targets in acute myeloid leukemia, highlighting potential treatment pathways.

This research aims to classify acute myeloid leukemia (AML) subtypes and find associated therapeutic targets through a multiomics approach.
Analyzed 173 treatment-naive individuals with AML using 13 modalities of proteogenomic and metabolomic profiling.
Developed a multiomic machine-learning approach to identify therapeutic targets across AML subtypes.
Evaluated the relationship between metabolic changes and protein hyperacetylation in CEBPA-mutant AML.
Identified distinct AML subtypes based on integrating proteogenomic and metabolomic data.
Found significant metabolic and lipidomic alterations linked to MYC and mTOR activity.
Validated MTA1 as a target related to resistance against panobinostat.

Chu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark